RU2018130123A - Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии - Google Patents

Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии Download PDF

Info

Publication number
RU2018130123A
RU2018130123A RU2018130123A RU2018130123A RU2018130123A RU 2018130123 A RU2018130123 A RU 2018130123A RU 2018130123 A RU2018130123 A RU 2018130123A RU 2018130123 A RU2018130123 A RU 2018130123A RU 2018130123 A RU2018130123 A RU 2018130123A
Authority
RU
Russia
Prior art keywords
cell
tcr
cells
expressing
peptide antigen
Prior art date
Application number
RU2018130123A
Other languages
English (en)
Russian (ru)
Other versions
RU2018130123A3 (cg-RX-API-DMAC7.html
Inventor
Томас М. ШМИТТ
Филип Д. ГРИНБЕРГ
Original Assignee
Фред Хатчинсон Кансэр Рисёч Сентер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фред Хатчинсон Кансэр Рисёч Сентер filed Critical Фред Хатчинсон Кансэр Рисёч Сентер
Publication of RU2018130123A publication Critical patent/RU2018130123A/ru
Publication of RU2018130123A3 publication Critical patent/RU2018130123A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/065—Thymocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1394—Bone marrow stromal cells; whole marrow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
RU2018130123A 2012-05-03 2013-05-02 Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии RU2018130123A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642358P 2012-05-03 2012-05-03
US61/642,358 2012-05-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2014148286A Division RU2665548C2 (ru) 2012-05-03 2013-05-02 Способ получения клеток, экспрессирующих т-клеточный рецептор

Publications (2)

Publication Number Publication Date
RU2018130123A true RU2018130123A (ru) 2018-11-07
RU2018130123A3 RU2018130123A3 (cg-RX-API-DMAC7.html) 2022-04-12

Family

ID=49514896

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018130123A RU2018130123A (ru) 2012-05-03 2013-05-02 Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии
RU2014148286A RU2665548C2 (ru) 2012-05-03 2013-05-02 Способ получения клеток, экспрессирующих т-клеточный рецептор

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2014148286A RU2665548C2 (ru) 2012-05-03 2013-05-02 Способ получения клеток, экспрессирующих т-клеточный рецептор

Country Status (17)

Country Link
US (2) US9751928B2 (cg-RX-API-DMAC7.html)
EP (1) EP2844743B1 (cg-RX-API-DMAC7.html)
JP (2) JP6251734B2 (cg-RX-API-DMAC7.html)
KR (2) KR20150009556A (cg-RX-API-DMAC7.html)
CN (2) CN104395462B (cg-RX-API-DMAC7.html)
AU (2) AU2013256159B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014027374B1 (cg-RX-API-DMAC7.html)
CA (1) CA2872471C (cg-RX-API-DMAC7.html)
ES (1) ES2858248T3 (cg-RX-API-DMAC7.html)
IL (1) IL235355B (cg-RX-API-DMAC7.html)
IN (1) IN2014DN09787A (cg-RX-API-DMAC7.html)
MX (1) MX361760B (cg-RX-API-DMAC7.html)
NZ (1) NZ702108A (cg-RX-API-DMAC7.html)
PH (1) PH12014502418B1 (cg-RX-API-DMAC7.html)
RU (2) RU2018130123A (cg-RX-API-DMAC7.html)
SG (2) SG11201407175RA (cg-RX-API-DMAC7.html)
WO (1) WO2013166321A1 (cg-RX-API-DMAC7.html)

Families Citing this family (294)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006304573B2 (en) 2005-10-17 2012-05-24 Sloan Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
IL286053B2 (en) 2005-10-18 2023-03-01 Nat Jewish Health A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin
ES2591029T3 (es) 2006-04-10 2016-11-24 Sloan Kettering Institute For Cancer Research Péptidos WT-1 inmunogénicos y métodos para su uso
AU2009246876B2 (en) 2008-05-16 2015-04-02 Htyr Acquisition Llc Antibodies and processes for preparing the same
ES2879225T3 (es) 2008-08-28 2021-11-22 Taiga Biotechnologies Inc Moduladores de MYC, métodos de uso de los mismos, y métodos para identificar agentes que modulan MYC
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
ES2856179T3 (es) 2012-07-20 2021-09-27 Taiga Biotechnologies Inc Reconstitución y autorreconstitución potenciadas del compartimento hematopoyético
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
PL2945647T3 (pl) 2013-01-15 2021-03-08 Memorial Sloan Kettering Cancer Center Immunogenne peptydy wt-1 i sposoby ich zastosowania
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
AU2014352826B2 (en) * 2013-11-22 2019-08-01 The Board Of Trustees Of The University Of Illinois Engineered high-affinity human T cell receptors
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
CA2954414A1 (en) 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US10538572B2 (en) 2014-08-04 2020-01-21 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for WT-1
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
WO2016064929A1 (en) 2014-10-20 2016-04-28 Juno Therapeutics, Inc. Methods and compositions for dosing in adoptive cell therapy
KR102635942B1 (ko) 2014-11-05 2024-02-14 주노 쎄러퓨티크스 인코퍼레이티드 형질도입 및 세포 프로세싱을 위한 방법
CN107206025A (zh) 2014-12-03 2017-09-26 朱诺治疗学股份有限公司 用于过继细胞治疗的方法和组合物
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
WO2016115559A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
KR20180010229A (ko) 2015-05-20 2018-01-30 더 브로드 인스티튜트, 인코퍼레이티드 공유 신생항원
CN108174607A (zh) 2015-05-29 2018-06-15 朱诺治疗学股份有限公司 用于遗传工程改造的细胞中调节抑制性相互作用的组合物和方法
AU2016279062A1 (en) 2015-06-18 2019-03-28 Omar O. Abudayyeh Novel CRISPR enzymes and systems
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
RU2757135C2 (ru) 2015-09-24 2021-10-11 АБВИТРО ЭлЭлСи Композиции антител к вич и способы их применения
US10928392B2 (en) 2015-09-25 2021-02-23 Abvitro Llc High throughput process for T cell receptor target identification of natively-paired T cell receptor sequences
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MX395154B (es) 2015-10-22 2025-03-25 Juno Therapeutics Gmbh Métodos, kits, agentes y aparatos para transducción.
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
MA44314A (fr) 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
CA3005878A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
CA3007258A1 (en) 2015-12-03 2017-06-08 Mark L. Bonyhadi Compositions and methods for reducing immune responses against cell therapies
CA3007262A1 (en) 2015-12-03 2017-06-08 Lucas James Thompson Modified chimeric receptors and related compositions and methods
ES2901795T3 (es) 2015-12-04 2022-03-23 Juno Therapeutics Inc Métodos y composiciones relacionadas con la toxicidad asociada con la terapia celular
EP3394092A1 (en) 2015-12-23 2018-10-31 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
EP3430548A1 (en) 2016-03-16 2019-01-23 Juno Therapeutics, Inc. Methods for determining dosing of a therapeutic agent and related treatments
US20190355459A1 (en) 2016-03-16 2019-11-21 Juno Therapeutics, Inc. Methods for adaptive design of a treatment regimen and related treatments
WO2017165571A1 (en) 2016-03-22 2017-09-28 Seattle Children's Hospital (dba Seattle Children's Research Institute) Early intervention methods to prevent or ameliorate toxicity
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
MA44869A (fr) 2016-05-06 2019-03-13 Editas Medicine Inc Cellules génétiquement modifiées et leurs procédés de fabrication
EP3452514A1 (en) 2016-05-06 2019-03-13 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for mart-1
WO2017205846A1 (en) 2016-05-27 2017-11-30 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of genome-editing molecules
WO2017210689A1 (en) 2016-06-03 2017-12-07 Memorial Sloan-Kettering Cancer Center Adoptive cell therapies as early treatment options
MA45341A (fr) 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
CN110291402B (zh) 2016-06-27 2023-09-01 朱诺治疗学股份有限公司 鉴定肽表位的方法、结合此类表位的分子和相关用途
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
KR20230107408A (ko) 2016-07-29 2023-07-14 주노 쎄러퓨티크스 인코퍼레이티드 항-cd19 항체에 대한 항-이디오타입 항체
WO2018023093A1 (en) 2016-07-29 2018-02-01 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods
CN109804089A (zh) 2016-07-29 2019-05-24 朱诺治疗学股份有限公司 用于评估复制型病毒存在或不存在的方法
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
RU2755725C2 (ru) 2016-09-12 2021-09-20 Джуно Терапьютикс, Инк. Сборочные узлы перфузионных биореакторных мешков
WO2018064208A1 (en) 2016-09-28 2018-04-05 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
EP3518943A4 (en) 2016-09-28 2020-04-22 Atossa Therapeutics, Inc. METHOD FOR ADAPTIVE CELL THERAPY
MA46354A (fr) 2016-10-03 2019-08-07 Juno Therapeutics Inc Molécules se liant spécifiquement au vph
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
MX2019004181A (es) 2016-10-13 2019-10-30 Juno Therapeutics Inc Métodos y composiciones de inmunoterapia que implican moduladores de la ruta metabólica de triptófano.
CA3040914A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
MX2019005029A (es) 2016-11-03 2019-10-24 Juno Therapeutics Inc Terapia de combinación de una terapia de células t y un inhibidor de tirosina cinasa de bruton (btk).
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
EP3538113A4 (en) * 2016-11-14 2020-08-19 Fred Hutchinson Cancer Research Center HIGH AFFINITY MERKEL CELL POLYOMAVIRUS T ANTIGEN SPECIFIC TCRs AND THEIR USES
CN113307858A (zh) 2016-12-02 2021-08-27 泰加生物工艺学公司 纳米颗粒调配物
CN110545826A (zh) 2016-12-03 2019-12-06 朱诺治疗学股份有限公司 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物
CA3045355A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
KR20230156808A (ko) 2016-12-03 2023-11-14 주노 쎄러퓨티크스 인코퍼레이티드 Car-t 세포의 조절 방법
CA3045338A1 (en) 2016-12-05 2018-06-14 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
CN110691792A (zh) 2017-01-10 2020-01-14 朱诺治疗学股份有限公司 细胞疗法的表观遗传学分析及相关方法
JP2020505034A (ja) 2017-01-20 2020-02-20 ジュノ セラピューティクス ゲーエムベーハー 細胞表面コンジュゲートならびに関連する細胞組成物および方法
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
BR112019016657A2 (pt) 2017-02-12 2020-04-07 Neon Therapeutics, Inc. métodos baseados em hla e composições e usos destes
EP3582782B1 (en) 2017-02-17 2023-06-07 Fred Hutchinson Cancer Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
CN110582287A (zh) 2017-02-27 2019-12-17 朱诺治疗学股份有限公司 与在细胞疗法中给药有关的组合物、制品和方法
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
EA201992155A1 (ru) 2017-03-14 2020-03-16 Джуно Терапьютикс, Инк. Способы криогенного хранения
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
EP3606518A4 (en) 2017-04-01 2021-04-07 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
EP3606550A2 (en) 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof
EP3607319A1 (en) 2017-04-07 2020-02-12 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
US20200071773A1 (en) 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
US11796534B2 (en) 2017-04-14 2023-10-24 Juno Therapeutics, Inc. Methods for assessing cell surface glycosylation
US20210293783A1 (en) 2017-04-18 2021-09-23 The General Hospital Corporation Compositions for detecting secretion and methods of use
KR102668891B1 (ko) 2017-04-18 2024-05-29 후지필름 셀룰러 다이내믹스, 인코포레이티드 항원-특이적 면역 이펙터 세포
BR112019022356A2 (pt) 2017-04-27 2020-05-26 Juno Therapeutics Gmbh Reagentes de partícula oligoméricos e métodos de uso dos mesmos
IL310031A (en) 2017-05-01 2024-03-01 Juno Therapeutics Inc A combination of cellular therapy and an immune modulatory compound
EP3622092A4 (en) 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
US12297436B2 (en) 2017-05-18 2025-05-13 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
WO2018218038A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
EP3630132A1 (en) 2017-06-02 2020-04-08 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
CA3064597A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
EP3638218A4 (en) 2017-06-14 2021-06-09 The Broad Institute, Inc. COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
LT3538645T (lt) 2017-06-20 2021-04-26 Institut Curie Suv39h1 atžvilgiu defektyvios imuninės ląstelės
WO2018237300A1 (en) 2017-06-22 2018-12-27 Board Of Regents, The University Of Texas System METHODS OF GENERATING REGULATORY IMMUNE CELLS AND USES THEREOF
US20220225597A1 (en) 2017-06-29 2022-07-21 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
WO2019027850A1 (en) 2017-07-29 2019-02-07 Juno Therapeutics, Inc. CELL EXPANSION REAGENTS EXPRESSING RECOMBINANT RECEPTORS
WO2019027465A1 (en) 2017-08-03 2019-02-07 Taiga Biotechnologies, Inc. PHARMACEUTICAL METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
KR102755437B1 (ko) 2017-08-09 2025-01-20 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법
JP2020530294A (ja) 2017-08-09 2020-10-22 ジュノー セラピューティクス インコーポレイテッド 遺伝子操作された細胞を調製するための方法および組成物
EP3676403A1 (en) 2017-09-01 2020-07-08 Juno Therapeutics, Inc. Gene expression and assessment of risk of developing toxicity following cell therapy
US20200292526A1 (en) 2017-09-07 2020-09-17 Juno Therapeutics, Inc. Methods of identifying cellular attributes related to outcomes associated with cell therapy
CN109517820B (zh) 2017-09-20 2021-09-24 北京宇繁生物科技有限公司 一种靶向HPK1的gRNA以及HPK1基因编辑方法
KR102338449B1 (ko) 2017-09-21 2021-12-10 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물
EP3695408A4 (en) 2017-10-02 2021-12-15 The Broad Institute, Inc. PROCEDURES AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANT GENE SIGNATURE IN CANCER
CN111954679A (zh) 2017-10-03 2020-11-17 朱诺治疗学股份有限公司 Hpv特异性结合分子
JP2021500878A (ja) 2017-10-12 2021-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法のためのｔ細胞受容体
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
ES2999361T3 (en) 2017-11-01 2025-02-25 Juno Therapeutics Inc Process for generating therapeutic compositions of engineered cells
US20210254000A1 (en) 2017-11-01 2021-08-19 Juno Therapeutics, Inc. Process for producing a t cell composition
KR20200075000A (ko) 2017-11-01 2020-06-25 에디타스 메디신, 인코포레이티드 면역요법을 위한 t 세포 내 tgfbr2의 crispr-cas9 편집 방법, 조성물 및 성분
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
CA3080904A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019090364A1 (en) 2017-11-06 2019-05-09 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
CN111556893A (zh) 2017-11-06 2020-08-18 爱迪塔斯医药股份有限公司 免疫疗法t细胞中cblb的crispr-cas9编辑的方法、组合物和组分
MA50571A (fr) 2017-11-10 2020-09-16 Juno Therapeutics Inc Réservoirs cryogéniques à système fermé
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
US12171783B2 (en) 2017-11-13 2024-12-24 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
US20210198372A1 (en) 2017-12-01 2021-07-01 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
WO2019113557A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
SG11202005217VA (en) 2017-12-08 2020-07-29 Juno Therapeutics Inc Phenotypic markers for cell therapy and related methods
CN112041430A (zh) 2017-12-08 2020-12-04 朱诺治疗学股份有限公司 用于培养细胞的无血清培养基配制品及其使用方法
KR102637862B1 (ko) * 2017-12-13 2024-02-19 이노비오 파마수티컬즈, 인크. 메소텔린을 표적으로 하는 암 백신 및 이의 용도
EP3724225A1 (en) 2017-12-15 2020-10-21 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
US11919937B2 (en) 2018-01-09 2024-03-05 Board Of Regents, The University Of Texas System T cell receptors for immunotherapy
CN112055595B (zh) 2018-01-22 2024-12-17 恩多塞特公司 Car t细胞的使用方法
CN111971059A (zh) 2018-01-31 2020-11-20 细胞基因公司 使用过继细胞疗法和检查点抑制剂的组合疗法
WO2019152747A1 (en) 2018-01-31 2019-08-08 Juno Therapeutics, Inc. Methods and reagents for assessing the presence or absence of replication competent virus
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
EP3762012A1 (en) 2018-03-09 2021-01-13 Ospedale San Raffaele S.r.l. Il-1 antagonist and toxicity induced by cell therapy
MX2020010460A (es) 2018-04-05 2021-01-29 Juno Therapeutics Inc Receptores de células t, y células diseñadas que expresan los mismos.
MX2020010459A (es) 2018-04-05 2021-01-20 Juno Therapeutics Inc Metodos para producir celulas que expresan un receptor recombinante y composiciones relacionadas.
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
MX2020011527A (es) 2018-05-03 2021-02-26 Juno Therapeutics Inc Terapia de combinación de una terapia de células t-receptor de antígeno quimérico (car) y un inhibidor de cinasa.
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2019246286A1 (en) 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Neoantigens and uses thereof
IL280659B2 (en) 2018-08-09 2024-11-01 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
CA3108698A1 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for assessing integrated nucleic acids
WO2020068304A2 (en) 2018-08-20 2020-04-02 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
WO2020041387A1 (en) 2018-08-20 2020-02-27 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
WO2020041384A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
JP7504891B2 (ja) 2018-09-11 2024-06-24 ジュノー セラピューティクス インコーポレイテッド 操作された細胞組成物のマススペクトロメトリー分析のための方法
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
SG11202104355SA (en) 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
AU2019374790A1 (en) 2018-11-06 2021-05-27 Juno Therapeutics, Inc. Process for producing genetically engineered T cells
EP3876958A1 (en) 2018-11-08 2021-09-15 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
EP3880238A1 (en) 2018-11-16 2021-09-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
JP7630832B2 (ja) 2018-11-19 2025-02-18 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｃａｒおよびｔｃｒ形質導入用のモジュール式ポリシストロニックベクター
KR20210096638A (ko) 2018-11-28 2021-08-05 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 억제성 환경에 대한 기능 및 내성을 증진시키기 위한 면역 세포의 멀티플렉스 게놈 편집
MX2021006393A (es) 2018-11-29 2021-10-13 Univ Texas Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
PL3886875T3 (pl) 2018-11-30 2024-09-09 Juno Therapeutics, Inc. Metody leczenia z wykorzystaniem adoptywnej terapii komórkowej
IL316112A (en) 2018-11-30 2024-12-01 Juno Therapeutics Inc Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
MX2021007556A (es) 2018-12-21 2021-09-10 Biontech Us Inc Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+.
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
BR112021014833A2 (pt) 2019-01-29 2021-10-05 Juno Therapeutics, Inc. Anticorpos e receptores antigênicos quiméricos específicos para receptor órfão 1 de tipo tirosina quinase de receptor (ror1)
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US20220142948A1 (en) 2019-03-18 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
AU2020272664A1 (en) 2019-04-08 2021-11-04 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
US20220184131A1 (en) 2019-05-01 2022-06-16 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
SG11202111372VA (en) 2019-05-01 2021-11-29 Juno Therapeutics Inc Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
CA3137031A1 (en) 2019-05-14 2020-11-19 Yosef Refaeli Compositions and methods for treating t cell exhaustion
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
US20220228101A1 (en) 2019-06-07 2022-07-21 Juno Therapeutics, Inc. Automated t cell culture
SG11202113356XA (en) 2019-06-12 2021-12-30 Juno Therapeutics Inc Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
BR112022001148A2 (pt) 2019-07-23 2022-03-15 Inst Nat Sante Rech Med Células imunes modificadas, composição farmacêutica, kit, uso de uma célula imune modificada e invenção de produto
US12480958B2 (en) 2019-08-13 2025-11-25 Immatics Biotechnologies Gmbh Method for the characterization of peptide:MHC binding polypeptides
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
EP4017527A1 (en) 2019-08-22 2022-06-29 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
US12444491B2 (en) 2019-08-30 2025-10-14 Juno Therapeutics, Inc. Machine learning methods for classifying cells
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
CA3158775A1 (en) 2019-09-02 2021-03-11 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
CA3153700A1 (en) 2019-09-09 2021-03-18 Scribe Therapeutics Inc. Compositions and methods for use in immunotherapy
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US20220401539A1 (en) 2019-10-22 2022-12-22 Institut Curie Immunotherapy Targeting Tumor Neoantigenic Peptides
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
IL292319B1 (en) 2019-10-30 2025-09-01 C3S2 Gmbh Cell selection and/or stimulation devices and methods of use
MX2022005524A (es) 2019-11-07 2022-08-25 Juno Therapeutics Inc Combinacion de una terapia de celulas t y (s)-3-[4-(4-morfolin-4-i lmetil-benciloxi)-1-oxo-1,3-dihidro-isoindol-2-il]-piperidino-2,6 -diona.
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
CN115398231A (zh) 2019-12-06 2022-11-25 朱诺治疗学股份有限公司 与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法
KR20220122656A (ko) 2019-12-06 2022-09-02 주노 쎄러퓨티크스 인코퍼레이티드 Ｇｐｒｃ5ｄ-표적화 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법
CN115916817A (zh) 2019-12-06 2023-04-04 朱诺治疗学股份有限公司 针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
WO2021151008A1 (en) 2020-01-24 2021-07-29 Juno Therapuetics, Inc. Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
CN115427550A (zh) 2020-01-28 2022-12-02 朱诺治疗学股份有限公司 T细胞转导方法
KR20220152227A (ko) 2020-02-12 2022-11-15 주노 쎄러퓨티크스 인코퍼레이티드 Ｂｃｍａ-지시된 키메라 항원 수용체 ｔ 세포 조성물 및 이의 방법 및 용도
IL295384A (en) 2020-02-12 2022-10-01 Juno Therapeutics Inc Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
WO2021167908A1 (en) 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
KR20230009386A (ko) 2020-04-10 2023-01-17 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021228999A1 (en) 2020-05-12 2021-11-18 Institut Curie Neoantigenic epitopes associated with sf3b1 mutations
US20230178239A1 (en) 2020-05-13 2023-06-08 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
KR20230022868A (ko) 2020-05-13 2023-02-16 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
CN115803084A (zh) 2020-05-21 2023-03-14 得克萨斯大学体系董事会 具有vgll1特异性的t细胞受体和其用途
CN116234558A (zh) 2020-06-26 2023-06-06 朱诺治疗学有限公司 条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
KR20230074713A (ko) 2020-07-30 2023-05-31 엥스띠뛰 퀴리 Socs1에 결함이 있는 면역 세포
JP2023536326A (ja) 2020-08-05 2023-08-24 ジュノー セラピューティクス インコーポレイテッド Ｒｏｒ１標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
JP2023538647A (ja) 2020-08-21 2023-09-08 １２３４３０９６ カナダ インク． モジュール型アセンブリ受容体およびその使用
CN114106144B (zh) * 2020-08-27 2024-01-26 溧阳瑅赛生物医药有限公司 识别hla-a*02/wt1靶点的tcr及其应用
EP4232071A4 (en) 2020-10-23 2024-08-28 Asher Biotherapeutics, Inc. FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
US20230051406A1 (en) 2020-11-13 2023-02-16 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
AU2022206324A1 (en) 2021-01-11 2023-07-20 Sana Biotechnology, Inc. Use of cd8-targeted viral vectors
WO2022187280A1 (en) 2021-03-01 2022-09-09 Dana-Farber Cancer Institute, Inc. Personalized redirection and reprogramming of t cells for precise targeting of tumors
WO2022187406A1 (en) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
JP2024510217A (ja) 2021-03-11 2024-03-06 アンスティテュ・クリー 膜貫通ネオ抗原ペプチド
US20250302929A1 (en) 2021-03-11 2025-10-02 Institut Curie Tumor neoantigenic peptides
CA3213004A1 (en) 2021-03-11 2022-09-15 Mnemo Therapeutics Tumor neoantigenic peptides and uses thereof
CN117321417A (zh) 2021-03-22 2023-12-29 朱诺治疗学股份有限公司 确定治疗性细胞组合物的效力的方法
CN117321200A (zh) 2021-03-22 2023-12-29 朱诺治疗学股份有限公司 评估病毒载体颗粒效力的方法
AU2022246593A1 (en) 2021-03-29 2023-10-12 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
BR112023020012A2 (pt) 2021-03-29 2023-11-14 Juno Therapeutics Inc Combinação de uma terapia de células t que expressam car e um composto imunomodulador para o tratamento de linfoma
EP4326293A4 (en) 2021-04-22 2025-03-12 Baylor College of Medicine METHODS FOR MODIFYING IMMUNE CELLS HAVING REDUCED FRATRICIDAL ACTIVITY
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
AU2022324040A1 (en) 2021-08-04 2024-02-22 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
WO2023015217A1 (en) 2021-08-04 2023-02-09 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023105000A1 (en) 2021-12-09 2023-06-15 Zygosity Limited Vector
WO2023115039A2 (en) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
TW202342757A (zh) 2021-12-17 2023-11-01 美商薩那生物科技公司 經修飾副黏液病毒科附著醣蛋白
CA3244649A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics IMMUNE CELLS WITH INACTIVATED SUV39H1 AND MODIFIED TCR
CN120077132A (zh) 2022-01-21 2025-05-30 姆内莫治疗公司 Rna对suv39h1表达的调控
US20250101379A1 (en) 2022-01-28 2025-03-27 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
EP4472646A1 (en) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
CA3245554A1 (en) 2022-03-18 2023-09-21 The Regents Of The University Of Colorado, A Body Corporate Genetically modified T lymphocyte co-receptors and their methods of use
US20250302930A1 (en) 2022-03-24 2025-10-02 Institut Curie Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023196921A1 (en) 2022-04-06 2023-10-12 The Regents Of The University Of Colorado, A Body Corporate Granzyme expressing t cells and methods of use
WO2023196933A1 (en) 2022-04-06 2023-10-12 The Regents Of The University Of Colorado, A Body Corporate Chimeric antigen receptor t cells and methods of use thereof
US20250235478A1 (en) 2022-04-28 2025-07-24 Musc Foundation For Research Development Chimeric antigen receptor modified regulatory t cells for treating cancer
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
CN119546638A (zh) 2022-06-22 2025-02-28 朱诺治疗学股份有限公司 用于cd19靶向的car t细胞的二线疗法的治疗方法
WO2024006960A1 (en) 2022-06-29 2024-01-04 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids
CA3264572A1 (en) 2022-08-26 2024-02-29 Juno Therapeutics, Inc. DELTA-TYPE CHIMERICAL ANTIBODIES AND ANTIGENIC RECEPTORS (DLL3)
JP2025531850A (ja) 2022-09-08 2025-09-25 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法および継続的または間欠的ｄｇｋ阻害剤投薬の組合せ
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
KR20250121074A (ko) 2022-12-09 2025-08-11 주노 쎄러퓨티크스 인코퍼레이티드 홀로그래픽 이미징을 사용하여 세포 표현형을 예측하기 위한 기계 학습 방법
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
AU2024230609A1 (en) 2023-02-28 2025-09-04 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
KR20250169631A (ko) 2023-04-18 2025-12-03 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
WO2024220574A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
WO2024220560A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
WO2024220598A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Lentiviral vectors with two or more genomes
WO2024226838A2 (en) 2023-04-25 2024-10-31 The Brigham And Women's Hospital, Inc. Treatment of autoimmune diseases having a pathogenic t cell state
WO2024226858A1 (en) 2023-04-26 2024-10-31 Juno Therapeutics, Inc. Methods for viral vector manufacturing
WO2024243365A2 (en) 2023-05-23 2024-11-28 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation
WO2025054202A1 (en) 2023-09-05 2025-03-13 Sana Biotechnology, Inc. Method of screening a sample comprising a transgene with a unique barcode
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025082603A1 (en) 2023-10-18 2025-04-24 Institut Curie Engineered immune cells overexpressing cd74 molecule
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025096975A1 (en) 2023-11-02 2025-05-08 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of enhancing immune cell therapies by runx2 modulation
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
WO2025151838A1 (en) 2024-01-12 2025-07-17 Sana Biotechnology, Inc. Safety switches to control in vitro and in vivo proliferation of cell therapy products
WO2025163107A1 (en) 2024-02-01 2025-08-07 Institut Gustave Roussy Immune cells defective for znf217 and uses thereof
WO2025184421A1 (en) 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
WO2025235851A1 (en) 2024-05-10 2025-11-13 Juno Therapeutics, Inc. Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
US6541249B2 (en) 1999-12-22 2003-04-01 Human Genome Sciences, Inc. Immortalized human stromal cell lines
EP1118661A1 (en) 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut T cell receptor libraries
MXPA04005010A (es) * 2001-11-26 2005-04-08 Advanced Cell Tech Inc METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS.
US7575925B2 (en) 2002-12-10 2009-08-18 Sunnybrook Health Sciences Centre Cell preparations comprising cells of the T cell lineage and methods of making and using them
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
WO2006132524A1 (en) 2005-06-06 2006-12-14 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for generating a t cell against an antigen of interest.
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
US10059923B2 (en) * 2008-01-30 2018-08-28 Memorial Sloan Kettering Cancer Center Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
CA2743669C (en) 2008-11-24 2018-10-16 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) High affinity t cell receptor and use thereof

Also Published As

Publication number Publication date
CN107557334A (zh) 2018-01-09
AU2013256159B2 (en) 2018-08-09
SG10201609210SA (en) 2016-12-29
EP2844743A4 (en) 2015-12-30
EP2844743B1 (en) 2021-01-13
IL235355B (en) 2019-10-31
KR20150009556A (ko) 2015-01-26
SG11201407175RA (en) 2014-12-30
RU2018130123A3 (cg-RX-API-DMAC7.html) 2022-04-12
CN107557334B (zh) 2021-06-25
US9751928B2 (en) 2017-09-05
KR102276888B1 (ko) 2021-07-14
US10875904B2 (en) 2020-12-29
US20170362298A1 (en) 2017-12-21
BR112014027374B1 (pt) 2022-05-31
KR20210013284A (ko) 2021-02-03
CN104395462B (zh) 2017-09-26
MX2014013270A (es) 2015-02-05
ES2858248T3 (es) 2021-09-29
JP6251734B2 (ja) 2017-12-27
US20150118208A1 (en) 2015-04-30
PH12014502418A1 (en) 2015-01-12
AU2018260963A1 (en) 2018-11-29
IN2014DN09787A (cg-RX-API-DMAC7.html) 2015-07-31
JP2015521172A (ja) 2015-07-27
CN104395462A (zh) 2015-03-04
PH12014502418B1 (en) 2020-06-05
BR112014027374A2 (pt) 2017-06-27
RU2665548C2 (ru) 2018-08-30
RU2014148286A (ru) 2016-06-20
CA2872471C (en) 2022-11-22
EP2844743A1 (en) 2015-03-11
NZ702108A (en) 2016-09-30
JP6666323B2 (ja) 2020-03-13
JP2018042564A (ja) 2018-03-22
AU2018260963B2 (en) 2021-04-29
WO2013166321A1 (en) 2013-11-07
CA2872471A1 (en) 2013-11-07
IL235355A0 (en) 2014-12-31
AU2013256159A1 (en) 2014-11-13
MX361760B (es) 2018-12-17
HK1208050A1 (en) 2016-02-19

Similar Documents

Publication Publication Date Title
RU2018130123A (ru) Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии
TWI835730B (zh) Ｔｃｒ及肽
JP6712261B2 (ja) Ｗｔ−１に特異的なｔ細胞免疫治療
EP3795177B1 (en) Claudin-18.2-specific immunoreceptors and t cell epitopes
Quandt et al. Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses
RS58627B2 (sr) Klaudin-6-specifični imuno receptori i t-ćelijski epitopi
WO2015154012A1 (en) Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
CN103249430A (zh) 抗原特异性t细胞受体和t细胞表位
JP2024510217A (ja) 膜貫通ネオ抗原ペプチド
Moran et al. Immunotherapy expands and maintains the function of high-affinity tumor-infiltrating CD8 T cells in situ
KR20210018838A (ko) 유전자 조작된 세포 및 응용
WO2019055862A1 (en) HIGH AFFINITY T CELL RECEPTORS AND USES THEREOF
Leitner et al. Porcine SWC1 is CD52—Final determination by the use of a retroviral cDNA expression library
ES2877820T3 (es) Composiciones y métodos para la clonación rápida de receptores de células T
JP6692040B2 (ja) 成人ｔ細胞性白血病を含むｈｔｌｖ−１ウイルス感染に対する腫瘍抗原特異的ｔ細胞
WO2025250011A1 (en) Treatment for cancer
TW202449156A (zh) 抑制天然殺手細胞對細胞療法之細胞毒性
HK40049189B (en) Claudin-18.2-specific immunoreceptors and t cell epitopes
HK40049189A (en) Claudin-18.2-specific immunoreceptors and t cell epitopes
EA045443B1 (ru) Tcr и пептиды
HK40001734B (en) Compositions and methods for rapid cloning of t-cell receptors
HK40001734A (en) Compositions and methods for rapid cloning of t-cell receptors
Erkkilä The generation of a T reporter cell line based screening method for T-cell receptor functional